EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

D Al-Sarayfi iD, M Brink, M E D Chamuleau, R Brouwer, R S van Rijn, D Issa, W Deenik, G Huls, R Mous, J S P Vermaat iD, A Diepstra, J M Zijlstra und 2 weitere

American Journal of Hematology · 2024-02 · 99 (2) · 216-222

DOI: 10.1002/ajh.27151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 28.11.2023. Verfasst von D Al-Sarayfi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For elderly frail patients with diffuse large B‐cell lymphoma (DLBCL), an attenuated chemo‐immunotherapy strategy of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐miniCHOP) was introduced as a treatment option as from 2014 onward in the Netherlands. Although R‐miniCHOP is more tolerable, reduction of chemotherapy could negatively affect survival compared to R‐CHOP. The aim of this analysis was to assess survival of patients treated with R‐miniCHOP compared to R‐CHOP. DLBCL patients ≥65 years, newly diagnosed in 2014–2020, who received ≥1 cycle of R‐miniCHOP or R‐CHOP were identified in the Netherlands Cancer Registry, with survival follow‐up through 2022. Patients were propensity‐score‐matched for baseline characteristics. Main endpoints were progression‐free survival (PFS), overall survival (OS), and relative survival (RS). The use of R‐miniCHOP in DLBCL increased from 2% in 2014 to 15% in 2020. In total, 384 patients treated with R‐miniCHOP and 384 patients treated with R‐CHOP were included for comparison (median age; 81 years, stage 3–4; 68%). The median number of R‐(mini)CHOP cycles was 6 (range, 1–8). The 2‐year PFS, OS and RS were inferior for patients treated with R‐miniCHOP compared to R‐CHOP (PFS 51% vs. 68%, p < .01; OS 60% vs. 75%, p < .01; RS 69% vs. 86%, p < .01). In multivariable analysis, patients treated with R‐miniCHOP had higher risk of all‐cause mortality compared to patients treated with R‐CHOP (HR 1.73; 95%CI, 1.39–2.17). R‐miniCHOP is effective for most elderly patients. Although survival is inferior compared to R‐CHOP, the use of R‐miniCHOP as initial treatment is increasing. Therefore, fitness needs to be carefully weighed in treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseHumansAgedRituximabAntibodies, Monoclonal, Murine-DerivedVincristineDoxorubicinCyclophosphamidePrednisoneTreatment Outcome

Substanzen

RituximabAntibodies, Monoclonal, Murine-DerivedVincristineDoxorubicinCyclophosphamidePrednisone

Autor:innen und Institutionen

  • Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
  • Department of Hematology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.
  • Department of Hematology, Reinier de Graaf Gasthuis, Delft, The Netherlands.
  • Department of Hematology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
  • Department of Hematology, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands.

ORCID-Profile: D Al-Sarayfi, J S P Vermaat

Zitieren

APA

Al-Sarayfi, D., Brink, M., Chamuleau, M. E. D., Brouwer, R., van Rijn, R. S., Issa, D., Deenik, W., Huls, G., Mous, R., Vermaat, J. S. P., Diepstra, A., Zijlstra, J. M., van Meerten, T., & Nijland, M. (2024). R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study. American Journal of Hematology, 99(2), 216-222. https://doi.org/10.1002/ajh.27151

Vancouver

Al-Sarayfi D, Brink M, Chamuleau MED, Brouwer R, van Rijn RS, Issa D, et al. R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study. American Journal of Hematology. 2024;99(2):216-222. doi:10.1002/ajh.27151

BibTeX
@article{AlSarayfi2024,
  author = {Al-Sarayfi, D and Brink, M and Chamuleau, M E D and Brouwer, R and van Rijn, R S and Issa, D and Deenik, W and Huls, G and Mous, R and Vermaat, J S P and Diepstra, A and Zijlstra, J M and van Meerten, T and Nijland, M},
  title = {R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {2},
  pages = {216--222},
  doi = {10.1002/ajh.27151}
}
Kostenlos starten →